November 24, 2020 

Greetings from New York where we are winding down an unsettling year full of challenges but looking ahead to the New Year with hope. Our team continues to juggle pandemic work-life balance, embracing flexibility and new ways of working. This year-end newsletter highlights our advances despite the COVID-19 crisis and shares next steps in our work to enhance people-centered reproductive and maternal health care through research and strategic partnerships.

As you reflect on favorite charities to support for Giving Tuesday, we invite you to consider the list of milestones since 20 years of mifepristone access in the United States and share with others as a way to acknowledge Gynuity's contributions to the field. 

Cheers to a year ahead full of positive change and scientific advances!

Warm wishes,
Beverly Winikoff
Medical Abortion via Telemedicine Reaches Individuals in 28 Mexican States
Missed Period Pills Offer Another Option for People Seeking to Disrupt Pregnancy
Gynuity has recently published a study of mifepristone and misoprostol for treatment of delayed menses without prior pregnancy confirmation, otherwise known as “missed period pills.” Used in this way, the pills would still terminate a pregnancy if one were present, but people using the method could do so without knowing if they had been pregnant. The main aim of our study was to explore potential interest in missed period pills in the United States. We conducted the study in two states: one in the northeast with no major abortion restrictions; and one in the midwest with multiple major abortion restrictions. We enrolled 678 people across nine health centers and found interest was greatest (70%) among those who would be unhappy if pregnant. Key reasons for interest were to prevent, avoid or terminate pregnancy; and psychological or emotional benefits, including management of abortion stigma. Reasons for non-interest included concerns about safety or side effects, desire to be pregnant or have a baby, and not wanting to abort or hurt a fetus/baby. Our findings suggest that some people do not desire pregnancy confirmation before taking medications that might disrupt a pregnancy. As a result, if missed period pills were an option in the United States, demand might be substantial and wide-ranging across demographic groups. In light of these findings, an important next step is to assess the feasibility, acceptability and use of an actual missed period pills service. “Exploring Potential Interest in Missed Period Pills in two US States: Contraception 2020 Sep 9;S0010-7824(20)30337-1. doi: 10.1016/j.contraception.2020.08.014. Online ahead of print.”
Please consider supporting Gynuity for Giving Tuesday!
Read our Strategic Plan and consult our Resources and News to learn about our work.